UroGen Pharma, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UroGen Pharma, Ltd.
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.
Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology.
- Controlled Release
- Site Specific
- Drug Delivery